P275 COMBINED NEURO–HUMORAL MODULATION AND OUTCOME IN PATIENTS WITH CHRONIC HEART FAILURE AND MILDLY REDUCED OR PRESERVED EJECTION FRACTION

P275 COMBINED NEURO–HUMORAL MODULATION AND OUTCOME IN PATIENTS WITH CHRONIC HEART FAILURE AND MILDLY REDUCED OR PRESERVED EJECTION FRACTION

Abstract Background Drug therapy of patients with chronic heart failure (HF) with mildly reduced (HFmrEF) and preserved ejection fraction (HFpEF) remains a challenge. We aimed to assess whether escalating neuro–humoral–modulation (NHM) (renin–angiotensin system inhibitors (RASI), betablockers (BB),...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European heart journal supplements 2023-05, Vol.25 (Supplement_D), p.D147-D147
Hauptverfasser: Gori, M, Marini, M, Gonzini, L, Carigi, S, De Gennaro, L, Gentile, P, Leonardi, G, Orso, F, Tinti, D, Lucci, D, Iacoviello, M, Navazio, A, Ammirati, E, Municinò, A, Benvenuto, M, Cassaniti, L, Tavazzi, L, Maggioni, A, De Maria, R
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract Background Drug therapy of patients with chronic heart failure (HF) with mildly reduced (HFmrEF) and preserved ejection fraction (HFpEF) remains a challenge. We aimed to assess whether escalating neuro–humoral–modulation (NHM) (renin–angiotensin system inhibitors (RASI), betablockers (BB), mineralocorticoid receptor antagonists (MRA)) was differentially associated with outcome according to phenotype and age groups. Methods and Results Between 1999 and 2018 we recruited in a nationwide cardiology registry 4707 patients (HFmrEF n=2298, HFpEF n=2409) and classified them into 3 age groups: young (
ISSN:1520-765X
1554-2815
DOI:10.1093/eurheartjsupp/suad111.349